Nuveen Asset Management, LLC Albireo Pharma, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.01 - $23.78 $950,982 - $1.26 Million	-52,803 Reduced 56.74%	40,260 $870,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $910,231 - $1.47 Million	55,774 Added 149.57%	93,063 $1.8 Million
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $213,543 - $429,506	-11,518 Reduced 23.6%	37,289 $741,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $98,872 - $139,346	-4,130 Reduced 7.8%	48,807 $1.41 Million
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $78,275 - $115,585	-3,694 Reduced 6.52%	52,937 $1.09 Million
Q3 2021 Nov 12, 2021	BUY	$27.36 - $35.98 $12,941 - $17,018	473 Added 0.84%	56,631 $1.74 Million
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $109,097 - $139,184	-3,775 Reduced 6.3%	56,158 $1.98 Million
Q1 2021 May 17, 2021	SELL	$32.03 - $42.85 $2.83 Million - $3.78 Million	-88,239 Reduced 59.55%	59,933 $2.11 Million
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $2.33 Million - $3.11 Million	73,796 Added 99.22%	148,172 $5.56 Million
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $253,397 - $454,672	10,927 Added 17.22%	74,376 $2.48 Million
Q2 2020 Aug 14, 2020	BUY	$14.82 - $29.92 $178,284 - $359,937	12,030 Added 23.4%	63,449 $1.68 Million
Q1 2020 May 14, 2020	BUY	$11.67 - $27.23 $151,149 - $352,682	12,952 Added 33.67%	51,419 $841,000
Q4 2019 Feb 14, 2020	SELL	$16.92 - $28.96 $7,546 - $12,916	-446 Reduced 1.15%	38,467 $978,000
Q3 2019 Nov 14, 2019	BUY	$20.0 - $31.88 $29,280 - $46,672	1,464 Added 3.91%	38,913 $779,000
Q2 2019 Aug 15, 2019	BUY	$30.67 - $37.86 $1.15 Million - $1.42 Million	37,449 New	37,449 $1.21 Million

Others Institutions Holding ALBO

# of Institutions

Shares Held

865

Call Options Held

Put Options Held

View Full List

About ALBIREO PHARMA, INC.

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

More about ALBO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account